Zydus Lifesciences reported a 30% rise in net profit to Rs 1,023 crore for Q3 FY25, driven by strong sales in the US and India. Revenue grew 17% year-on-year to Rs 5,269 crore. The company aims for double-digit growth and improved profitability in FY25. Despite strong results, shares traded 1.79% lower at Rs 956 on the BSE.
